Application of macrophage-targeting RIPK1 and RIPK1 inhibitor in screening and preparing liver injury diagnosis and treatment medicine
The invention discloses application of macrophage-targeting RIPK1 and an RIPK1 inhibitor in screening and preparing a liver injury diagnosis and treatment medicine RIPK1 inactivated mouse bone marrow is transplanted into a normal C57 mouse to construct a non-alcoholic fatty liver, cirrhosis and hepatic fibrosis model, a result shows that the liver function of the mouse with transplanted RIPK1 inactivated bone marrow is obviously superior to that of a mouse with transplanted C57 mouse bone marrow, the contents of glutamic-pyruvic transaminase and triglyceride in serum are obviously reduced, a lipid component pathological staining result shows that the mouse with transplanted RIPK1 inactivated bone marrow can obviously relieve fatty liver lesion and significantly reduce lipid accumulation, and it is found that RIPK1 inactivation can significantly reduce inflammation and death of palmitic acid-induced bone marrow macrophages. A macrophage-targeting RIPK1 active site can be used as a medicine target for screening and treating liver injury diseases such as fatty liver, cirrhosis and hepatic fibrosis, and the RIPK1 inhibitor can be used for preparing the medicine for treating the liver injury diseases..
| Medienart: |
|
|---|
Patent| Erscheinungsjahr: |
2021 |
|---|---|
| Erschienen: |
2021 |
| Enthalten in: |
Europäisches Patentamt - (2021) vom: 06. Juli Zur Gesamtaufnahme - year:2021 |
|---|
| Sprache: |
Englisch |
|---|
| Beteiligte Personen: |
WENG DAN [VerfasserIn] |
|---|
| Links: |
Volltext [kostenfrei] |
|---|
| Anmerkungen: |
Source: www.epo.org (no modifications made), First posted: 2021-07-06, Last update posted on www.tib.eu: 2022-10-16, Last updated: 2023-02-09 |
|---|
| Patentnummer: |
CN113069546 |
|---|
| Förderinstitution / Projekttitel: |
|
|---|
| PPN (Katalog-ID): |
EPA014439514 |
|---|
| LEADER | 01000caa a22002652 4500 | ||
|---|---|---|---|
| 001 | EPA014439514 | ||
| 003 | DE-627 | ||
| 005 | 20230504150432.0 | ||
| 007 | cr uuu---uuuuu | ||
| 008 | 230215s2021 xx |||||o 00| ||eng c | ||
| 035 | |a (DE-627)EPA014439514 | ||
| 035 | |a (EPA)CN113069546 | ||
| 035 | |a (EPA)76608793 | ||
| 040 | |a DE-627 |b ger |c DE-627 |e rakwb | ||
| 041 | |a eng | ||
| 100 | 0 | |a WENG DAN |e verfasserin |4 aut | |
| 245 | 1 | 0 | |a Application of macrophage-targeting RIPK1 and RIPK1 inhibitor in screening and preparing liver injury diagnosis and treatment medicine |
| 264 | 1 | |c 2021 | |
| 336 | |a Text |b txt |2 rdacontent | ||
| 337 | |a Computermedien |b c |2 rdamedia | ||
| 338 | |a Online-Ressource |b cr |2 rdacarrier | ||
| 500 | |a Source: www.epo.org (no modifications made), First posted: 2021-07-06, Last update posted on www.tib.eu: 2022-10-16, Last updated: 2023-02-09 | ||
| 520 | |a The invention discloses application of macrophage-targeting RIPK1 and an RIPK1 inhibitor in screening and preparing a liver injury diagnosis and treatment medicine RIPK1 inactivated mouse bone marrow is transplanted into a normal C57 mouse to construct a non-alcoholic fatty liver, cirrhosis and hepatic fibrosis model, a result shows that the liver function of the mouse with transplanted RIPK1 inactivated bone marrow is obviously superior to that of a mouse with transplanted C57 mouse bone marrow, the contents of glutamic-pyruvic transaminase and triglyceride in serum are obviously reduced, a lipid component pathological staining result shows that the mouse with transplanted RIPK1 inactivated bone marrow can obviously relieve fatty liver lesion and significantly reduce lipid accumulation, and it is found that RIPK1 inactivation can significantly reduce inflammation and death of palmitic acid-induced bone marrow macrophages. A macrophage-targeting RIPK1 active site can be used as a medicine target for screening and treating liver injury diseases such as fatty liver, cirrhosis and hepatic fibrosis, and the RIPK1 inhibitor can be used for preparing the medicine for treating the liver injury diseases. | ||
| 650 | 4 | |a A61P: Specific therapeutic activity of chemical compounds or medicinal preparations | |
| 650 | 4 | |a che | |
| 650 | 4 | |a A61K: Preparations for medical, dental, or toilet purposes (devices or methods specially adapted for bringing pharmaceutical products into particular physical or administering forms a61j0003000000;chemical aspects of, or use of materials for deodorisation of air, for disinfection or sterilisation, or for bandages, dressings, absorbent pads or surgical articles a61l; soap compositions c11d) | |
| 650 | 4 | |a 615 | |
| 700 | 0 | |a YI YUGUO |4 aut | |
| 700 | 0 | |a TAO LIANG |4 aut | |
| 773 | 0 | 8 | |i Enthalten in |t Europäisches Patentamt |g (2021) vom: 06. Juli |
| 773 | 1 | 8 | |g year:2021 |g day:06 |g month:07 |
| 856 | 4 | 0 | |u https://worldwide.espacenet.com/patent/search/family/76608793/publication/CN113069546A1?q=CN113069546 |z kostenfrei |3 Volltext |
| 912 | |a GBV_EPA | ||
| 912 | |a SSG-OLC-PHA | ||
| 936 | u | w | |j 2021 |b 06 |c 07 |
| 951 | |a AR | ||
| 952 | |j 2021 |b 06 |c 07 | ||